Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor

Dear Editor:

We would like to address several challenges that have arisen from the study by Sakai et al. [1], which are specifically summarized below.

Several pertinent data are missing from the study (Table 1).
Table 1

Missing data from the article by Sakai et al. [1]


 The PCV duration before the entry into the study

 The duration of the aflibercept treatment prior to the start of triple therapy

 The anatomical types of macular edema (diffuse/subretinal fluid/cystic changes within neurosensory retina/mixed type) at index date and at month 12

 The proportion of patients with complete dry macula at the end of the study

 The anatomical lesions of the PCV (serous and hemorrhagic detachments of the RPE and neurosensory retina, exudative changes, aneurismal polypoidal lesions with overlying atrophy of the pigment epithelium, abnormal branch vascular networks, vitreous hemorrhage, subretinal fibrosis, pigment epithelial hyperplasia, and atrophic degeneration) at baseline and at the...


Compliance with ethical standards

Conflict of interest

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures.

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.


  1. 1.
    Sakai T, Kato N, Kubota M, Tsuneoka H (2017) Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255(8):1565–1571CrossRefPubMedGoogle Scholar
  2. 2.
    Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K (2013) Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol 91(6):e474–e481CrossRefPubMedGoogle Scholar
  3. 3.
    Jeong S, Sagong M (2017) Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Br J Ophthalmol 101(6):758–763CrossRefPubMedGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174(2):181–182PubMedGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2017) Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Eur J Ophthalmol 27(3):107–108Google Scholar
  6. 6.
    Călugăru D, Călugăru M (2017) Intravitreal dexamethasone implant as adjuvant treatment for bevacizumab- and ranibizumab-resistant neovascular age-related macular degeneration. Retina 37(6):78–79CrossRefGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovacular age-related macular degeneration. Am J Ophthalmol 173(1):145–146PubMedGoogle Scholar
  8. 8.
    Mukai R, Kishi S, Sato T, Watanabe G, Matsumoto H (2010) Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy. Ophthalmoloica 224(5):267–273CrossRefGoogle Scholar
  9. 9.
    Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMedGoogle Scholar
  10. 10.
    Julien S, Biesemeier A, Taubitz T, Schraemeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues on monkey eyes. Br J Ophthalmol 98(6):813–825CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations